Non-small cell lung cancer(NSCLC),miR-21,Autophagy,Proliferation,Apoptosis ,"/> miR-21靶向Atg5对非小细胞肺癌A549细胞自噬调控促进细胞增殖、迁移和侵袭的实验研究

临床肿瘤学杂志 ›› 2019, Vol. 24 ›› Issue (2): 97-101.

• •    下一篇

miR-21靶向Atg5对非小细胞肺癌A549细胞自噬调控促进细胞增殖、迁移和侵袭的实验研究

  

  1. 1  471003  河南洛阳  河南科技大学第一附属医院肿瘤内科

    2  450003  郑州大学附属肿瘤医院 河南省肿瘤医院肿瘤内科

  • 收稿日期:2018-09-05 修回日期:2018-10-31 接受日期:2018-10-31 出版日期:2019-02-28 发布日期:2019-03-18
  • 基金资助:

    *基金项目:国家自然科学基金资助项目(81172240)

Experimental study on the effect of miR-21 targeting Atg5 on the proliferation, migration and invasion of non-small cell lung cancer A549 cells by regulating autophagy

  1. Department of Oncology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003,China

  • Received:2018-09-05 Revised:2018-10-31 Accepted:2018-10-31 Online:2019-02-28 Published:2019-03-18

摘要: 目的  探讨miR-21通过靶向作用自噬相关靶基因5(Atg5)调控非小细胞肺癌(NSCLC)自噬的作用机制及其在A549细胞增殖、迁移及侵袭中的作用。方法  无义核酸序列NC(NC组)、miR-21 模拟物(miR-21 mimics组)、miR-21抑制物(miR-21 抑制组)分别转染A549细胞, CCK-8检测细胞增殖情况;划痕实验检测细胞迁移能力; Transwell侵袭实验检测细胞侵袭能力。双荧光素酶报告实验验证miR-21和Atg5之间的靶向关系。Western blotting检测LC3B-II、p62和Atg5蛋白的表达。结果  与NC组比较,miR-21 mimics组细胞增殖、迁移、侵袭能力均上调,miR-21 抑制组细胞增殖、迁移、侵袭能力均下调(P<0.05)。双荧光素酶报告实验结果显示,miR-21显著抑制野生型Atg5 3’-UTR质粒转染细胞的荧光素酶活性(P<0.05),但对突变型Atg5 3’-UTR的基因报告质粒与miR-21 mimics共转染之后,并未对荧光素酶活性产生影响。NC组LC3B-II蛋白表达量为1.24±0.059,低于miR-21 mimics组的1.98±0.077,高于miR-21抑制组的0.52±0.021(P<0.05);NC组p62蛋白表达量为0.62±0.021,高于miR-21 mimics组的0.45±0.020,低于miR-21抑制组的0.79±0.031(P<0.05);NC组Atg5蛋白表达量为1.17±0.025,高于miR-21 mimics组的0.38±0.014,低于miR-21抑制组的1.40±0.039(P<0.05)。与NC组比较, 3-MA处理降低miR-21 mimics转染诱导的A549细胞增殖能力(P<0.05);划痕实验和Transwell实验表明,3-MA处理抑制了miR-21mimics转染诱导的A549细胞的迁移和侵袭,差异有统计学意义(P<0.05)。结论  miR-21靶向Atg5调控NSCLC自噬促进细胞增殖、迁移和侵袭。

关键词: 非小细胞肺癌, miR-21, 自噬, 增殖, 凋亡

Abstract: Objective  To investigate the mechanism of miR-21 regulating autophagy of non-small cell lung cancer(NSCLC) by targeting autophagy-related target gene 5 (Atg5) and its role in proliferation, migration and invasion of A549 cells. Methods  Nonsense nucleic acid sequence NC (NC group), miR-21 mimics (miR-21 mimics group) and miR-21 inhibitor(miR-21 inhibitor group) were transfected into A549 cells, respectively. CCK-8 was used to detect the proliferation of A549 cells, scratch test was used to detect the migration ability of A549 cells, and Transwell invasion test was used to detect the invasion ability of A549 cells. Dual luciferase reporter gene assay verified the targeting relationship between miR-21 and Atg5. Western blotting was used to detect the expression of LC3B-II, p62 and Atg5 proteins. Results  Compared with NC group, the proliferation, migration and invasiveness of the cells in the miR-21 mimics group were up-regulated, while the proliferation, migration and invasiveness of the cells in the miR-21 inhibitor group were down-regulated (P<0.05). The results of double luciferase report experiment showed that miR-21 significantly inhibited the luciferase activity of wild-type Atg5 3’-UTR plasmid transfected cells (P<0.05), but had no effect on the luciferase activity after co-transfection of mutant Atg5 3’-UTR gene report plasmid with miR-21 mimics. The expression of LC3B-II protein in NC group was lower than that in miR-21 mimics group, higher than that in miR-21 inhibitor group (P<0.05); the expression of p62 and Atg5 protein in NC group was higher than that in miR-21 mimics group, lower than that in miR-21 inhibitor group  (P<0.05). Compared with NC group, 3-MA treatment decreased the proliferation of A549 cells induced by miR-21 mimics transfection (P<0.05). Scratch and Transwell experiments showed that 3-MA treatment inhibited the migration and invasion of A549 cells induced by miR-21 mimics transfection (P<0.05). Conclusion MiR-21 targeting Atg5 regulates autophagy in non-small cell lung cancer cells and promotes proliferation, migration and invasion of lung cancer cells.

Key words:

Non-small cell lung cancer(NSCLC)')">"> Non-small cell lung cancer(NSCLC), miR-21, Autophagy, Proliferation, Apoptosis

中图分类号: 

  • R734.2
[1] 叶 璐, 母 丹, 杨 莉, 付 波, 王 敏.

miR-582-5p靶向抑制Rab27a对肺癌细胞生物学行为的影响 [J]. 临床肿瘤学杂志, 2019, 24(2): 102-107.

[2] 张 宁, 卢创新, 务 森, 何 苡, 魏 立.

miR-138-5p在非小细胞肺癌中的表达及临床意义 [J]. 临床肿瘤学杂志, 2019, 24(2): 149-152.

[3] 葛 琴, 钱 霞, 谢国栋, 蔡 晶, 杨百霞, 吴建亭, 赵季忠, 崔娟娟, 朱兴华, 储春霞. EGFR和TGF-α在肺癌细胞放疗增敏中的作用[J]. 临床肿瘤学杂志, 2019, 24(2): 145-148.
[4] 杨三虎, 文苗苗, 张志培, 李维妙, 杨 锋, 李小飞.

非小细胞肺癌ROS1突变与EGFR突变及临床病理特征的关系 [J]. 临床肿瘤学杂志, 2019, 24(2): 175-178.

[5] 秦博宇, 宋 琪, 孙胜杰, 孙 琼, 陶 然, 焦顺昌.

外泌体在非小细胞肺癌获得性耐药中的研究进展 [J]. 临床肿瘤学杂志, 2019, 24(2): 179-182.

[6] 魏丹凤, 郭元彪, 王战豪, 朱义芳.  四川地区非小细胞肺癌患者EGFR基因突变分型与临床病理特征的相关性分析[J]. 临床肿瘤学杂志, 2018, 23(10): 915-919.
[7] 章余妹, 邵莉.  成人睾丸卵黄囊瘤1例[J]. 临床肿瘤学杂志, 2018, 23(10): 957-958.
[8] 张超, 牛意, 张洁, 姚学敏, 高鹏, 刘美月, 魏晓梅, 杨朝, 刘春玲, 张月恒, 李宏民, 孙国贵.  

miR-1253对肺腺癌细胞增殖与迁移侵袭能力的影响 [J]. 临床肿瘤学杂志, 2018, 23(10): 865-869.

[9] 王海涛, 杨敬贤, 率胜胜. 不同工作年限放疗技师对老年Ⅲ期非小细胞肺癌调强放疗疗效的影响[J]. 临床肿瘤学杂志, 2018, 23(5): 449-452.
[10] 刘华丽, 阮 鹏, 彭 敏, 袁静萍, 宋启斌, 韩 光. 阿帕替尼联合脑部放疗同步替莫唑胺治疗非典型肺类癌脑转移1例[J]. 临床肿瘤学杂志, 2018, 23(5): 476-478.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 向作林1,曾昭冲1,吴 铮1. 三维适形加量放疗联合射频热疗治疗局部晚期前列腺癌的临床观察[J]. 临床肿瘤学杂志, 2009, 14(4): 361 .
[2] 赵满仓1,魏文青1,刘 晶1,张 艳1,焦 娟1,付 瑶1,安 平1. MTT法抗肿瘤药敏试验影响因素的探讨[J]. 临床肿瘤学杂志, 2009, 14(4): 306 .
[3] 谢 可,张 明,梁 良,兰海涛,李宏敏. 重组人血管内皮抑制素联合化疗治疗晚期恶性肿瘤的临床观察[J]. 临床肿瘤学杂志, 2009, 14(5): 466 .
[4] 李燕雏1,骆竹媚1,田 野2,李 平1. p53基因联合腹腔热灌注化疗治疗精囊腺癌术后腹腔转移的探讨及文献复习[J]. 临床肿瘤学杂志, 2009, 14(5): 457 .
[5] 冯晓莉1,鲁海珍1,孙耘田1,应建明1,陈 雁2,石素胜1,刘秀云1,郭 蕾1,梁建明3. 肾透明细胞癌中Ki67指数、EGFR表达及DNA倍体的临床意义[J]. 临床肿瘤学杂志, 2009, 14(6): 505 .
[6] 吴 标,庄 武,黄 诚,徐振武,张 晶,黄韵坚. 多西紫杉醇联合重组人血管内皮抑制素二线治疗晚期非小细胞肺癌[J]. 临床肿瘤学杂志, 2009, 14(7): 634 .
[7] 王 琳,秦叔逵,钱 军,陈映霞,杨宁蓉,王 锋. 西妥昔单抗联合化疗治疗晚期结直肠癌的临床观察[J]. 临床肿瘤学杂志, 2009, 14(7): 628 .
[8] 孙 杰,姜丽娜,王 欣. 紫杉醇局部注射治疗恶性胸腔积液的临床观察[J]. 临床肿瘤学杂志, 2009, 14(8): 737 .
[9] 张自森,吴 敏,巴 楠,王利娟. 吉非替尼对于化疗失败的晚期肺腺癌的疗效及生存观察[J]. 临床肿瘤学杂志, 2009, 14(10): 912 .
[10] 蒋太生,徐 行,朱海明,王晓庆. 周剂量多西紫杉醇联合卡培他滨二线治疗晚期食管癌的临床观察[J]. 临床肿瘤学杂志, 2010, 15(5): 441 .